HIV-associated neurotoxicity and cognitive decline: Therapeutic implications

Area of Science:

• Neuroscience
• Virology
• Immunology

Background:

• Human immunodeficiency virus type 1 (HIV-1) infection can lead to a spectrum of neurological complications, including neuropathy and cognitive decline.
• Central nervous system deficits, such as generalized cortical atrophy and neuronal death, worsen with disease progression.
• Antiretroviral therapy (ART) can slow disease progression and reduce viral load in the brain, but HIV-associated dementia (HAD) remains a severe outcome.

Purpose of the Study:

• To review existing hypotheses regarding HIV neurotoxicity.
• To explore potential therapeutic strategies for mitigating nervous system dysfunction in HIV-1 patients.

Main Methods:

• This review synthesizes current research on HIV-1's impact on the neurological system.
• It examines direct and indirect mechanisms of HIV neurotoxicity, focusing on key proteins like Tat and gp120.
• The review discusses the cascade of systems involved in HIV-related neurotoxicity.

Main Results:

• HIV-1 infection causes a range of neurological issues, affecting motor and cognitive functions.
• HIV neurotoxicity involves direct and indirect pathways, with viral proteins Tat and gp120 playing significant roles.
• Generalized cortical atrophy and neuronal death are common hallmarks of advanced HIV-1 infection.

Conclusions:

• Understanding the complex mechanisms of HIV neurotoxicity is crucial for developing effective treatments.
• Targeting specific points in the neurotoxic cascade, potentially involving viral proteins, offers therapeutic promise.
• Further research into HIV-associated neurocognitive disorders (HAND) and HAD is essential for improving patient outcomes.